Nov. 14 at 9:31 PM
$GNPX 10-Q filed
https://www.sec.gov/ix?doc=/Archives/edgar/data/1595248/000143774925035191/gnpx20250930_10q.htm
• 2,270,346 shares outstanding as of Nov 13
• In Q3 they sold 341,223 shares under the Lincoln Park ELOC for net proceeds of
$2,943,734. Since Oct 1, they sold 326,750 shares under the Lincoln Park ELOC for net proceeds
$1,434,139
• Since Oct 1, they sold 242,537 shares under the ATM for net proceeds of
$1,006,740
• ACCLAIM-1: expects to complete the enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the study in 1H 2026 and expects the interim analysis in 2H 2026.
• ACCLAIM-3: expects to complete enrollment of the first 25 patients for interim analysis 1H 2026 and expects the interim analysis in 2H 2026.
